HSP90AA1 and hidradenitis suppurativa: Recent clinical investigations of the oral Hsp90 inhibitor RGRN - 305 in plaque-type psoriasis and hidradenitis suppurativa (HS) have provided promising evidence supporting the therapeutic relevance of Hsp90 inhibition in chronic inflammatory skin disorders (11, 34).